A series of landmark trials with ACE inhibitors in patients with LVD or HF such as VALsartan in Acute myocardial INfarction (VALIANT), Valsartan in Heart Failure Trial (Val-HeFT) and others have reported reductions in CV mortality and morbidity [22,23,25,27,28,31,32]. The gene discussed is ACE; the disease is myocardial infarction.